Laurus Labs Limited — Others, 27-01-2025: Rumour Verification - Regulation 30(11)

Laurus Labs has clarified recent media reports regarding a freeze on PEPFAR funding by the US government, which accounts for approximately 10% of the global HIV financing budget. The company believes that, despite potential funding challenges, its operations will remain unaffected due to the overall resilience of the ARV medicine market. Additionally, with the US re-engaging with the WHO, Laurus Labs anticipates no significant impact on its business. This update suggests a positive outlook for the company's operational stability, assuaging investor concerns regarding funding disruptions.